New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
13:05 EDTABTAbbott says over 2,000 patients to be included in phase 3 program for HCV
Abbott released details on its phase 3 hepatitis C registrational program following results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease in Boston. Topline intent-to-treat results from the 12-week, triple-DAA regimens with ribavirin presented at the AASLD meeting this week found that 97.5%, or 77 of 79, of treatment-na´ve GT1 patients and 93.3%, or 42 of 45, in GT1 null responder patients achieved SVR12. The phase 3 clinical trials are designed to evaluate safety and efficacy of a 12-week regimen of three direct acting antivirals, with and without ribavirin, for the treatment of HCV in genotype 1 non-cirrhotic, treatment-na´ve and treatment-experienced patients. An additional phase 3 trial will study triple-DAAs, with ribavirin, in patients with cirrhosis for 12 or 24 weeks. The phase 3 program, which is currently open for enrollment, will include more than 2,000 patients with HCV genotype 1, with trial sites in 29 countries. The DAAs in the studies include ABT-450/r, ABT-267 and ABT-333. Treatment duration will be 12 weeks in non-cirrhotic patients, and 12 or 24 weeks in cirrhotic patients. All patients will be followed for 48 weeks post-treatment. Co-formulated tablets of ABT-450/r and ABT-267 will be used in the phase 3 trials, the company said.
News For ABT From The Last 14 Days
Check below for free stories on ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent ABT news | >>
July 16, 2014
07:46 EDTABTAbbott reports Q2 ongoing EPS 54c, consenus 51c
Subscribe for More Information
July 15, 2014
15:19 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:40 EDTABTEarnings Preview: Abbott targets continued gains in emerging markets
Subscribe for More Information
11:13 EDTABTPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
06:15 EDTABTAbbott unit sale to Mylan 'a wash,' says Citigroup
Subscribe for More Information
July 14, 2014
16:30 EDTABTOn The Fly: Closing Wrap
Subscribe for More Information
12:21 EDTABTOn The Fly: Midday Wrap
Subscribe for More Information
11:13 EDTABTAbbott CEO aims to boost medical device line, Reuters says
Subscribe for More Information
09:16 EDTABTOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
08:55 EDTABTMylan says does not anticipate regulatory hurdles prohibiting close of deal
08:49 EDTABTMylan says Abbott assets unlike other mature generic drug portfolios
Subscribe for More Information
08:36 EDTABTMylan accretive tax inversion deal makes sense, says UBS
Subscribe for More Information
08:27 EDTABTMylan sees Abbott transaction to be 'immediately and significantly accretive'
Subscribe for More Information
08:26 EDTABTMylan sees $10B in pro forma 2014 sales after closing Abbott deal
Subscribe for More Information
08:12 EDTABTMylan says Abbott deal 'first in series' of planned transactions
Subscribe for More Information
07:28 EDTABTMylan to host conference call
Subscribe for More Information
07:20 EDTABTAbbott to host conference call
Conference call to discuss agreement to sell developed markets branded generics pharmaceuticals business to Mylan will be held on July 14 at 9:30 am. Webcast Link
06:33 EDTABTAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
06:33 EDTABTMylan to acquire Abbott assets in all-stock transaction valued at about $5.3B
Subscribe for More Information
06:31 EDTABTAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
1 | 2 | all recent ABT news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use